56 research outputs found

    Dynamics of tree diversity in undisturbed and logged subtropical rainforest in Australia

    Get PDF
    In subtropical rainforest in eastern Australia, changes in the diversity of trees were compared under natural conditions and eight silvicultural regimes over 35 years. In the treated plots basal area remaining after logging ranged from 12 to 58 m2 per ha. In three control plots richness differed little over this period. In the eight treated plots richness per plot generally declined after intervention and then gradually increased to greater than original diversity. After logging there was a reduction in richness per plot and an increase in species richness per stem in all but the lightest selective treatments. The change in species diversity was related to the intensity of the logging, however the time taken for species richness to return to pre-logging levels was similar in all silvicultural treatments and was not effected by the intensity of treatment. These results suggest that light selective logging in these forests mainly affects dominant species. The return to high diversity after only a short time under all silvicultural regimes suggests that sustainability and the manipulation of species composition for desired management outcomes is possible

    Essential Medicines at the National Level : The Global Asthma Network's Essential Asthma Medicines Survey 2014

    Get PDF
    Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013-2020 sets an 80% target for essential NCD medicines' availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013-2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system's capacity to address NCDs.Peer reviewe
    corecore